Brought to you by 
Paradigm Therapeutics gets £12mm in second round
20 Dec 2002
Executive Summary
University of Cambridge spin-off Paradigm Therapeutics (functional genomics) raised £12mm ($19mm) in a second round private placement co-led by BioMedical Sciences Investment Fund and Technomark Medical Ventures. Also participating was return investor Avlar BioVentures as well as Genmab, whose investment is the result of an April 2002 agreement with Paradigm to develop antibody therapeutics.
Deal Industry
- Pharmaceuticals
-
Biotechnology
-
Drug Discovery Tools
- Bioinformatics
- Genomics-Proteomics
-
Drug Discovery Tools
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Paradigm Therapeutics gets £12mm in second round
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice